Compare COFS & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COFS | ARVN |
|---|---|---|
| Founded | 1898 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.9M | 516.2M |
| IPO Year | 1995 | 2018 |
| Metric | COFS | ARVN |
|---|---|---|
| Price | $32.35 | $8.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 19 |
| Target Price | ★ $34.00 | $15.05 |
| AVG Volume (30 Days) | 103.8K | ★ 647.9K |
| Earning Date | 04-24-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ 0.91 | N/A |
| Revenue | $227,624,000.00 | ★ $262,600,000.00 |
| Revenue This Year | $22.13 | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $37.00 | ★ N/A |
| Revenue Growth | ★ 63.64 | N/A |
| 52 Week Low | $26.10 | $6.06 |
| 52 Week High | $34.90 | $14.22 |
| Indicator | COFS | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | 42.94 |
| Support Level | $32.26 | $7.90 |
| Resistance Level | $33.58 | $8.90 |
| Average True Range (ATR) | 1.07 | 0.31 |
| MACD | -0.12 | -0.01 |
| Stochastic Oscillator | 42.65 | 6.00 |
ChoiceOne Financial Services Inc is a full-service banking institution. It is engaged in the business of providing personal and business banking solutions, borrowing solutions, and treasury notes and bonds services. The bank's product and services portfolio consist of time, savings and demand deposits, safe deposit services, automated transaction machine services, commercial and consumer loans, commercial lending to business, industry, agricultural, construction, inventory, and real estate categories. Its primary market area is Kent, Muskegon, Newaygo, and Ottawa counties in western Michigan, and Lapeer, Macomb, and St. Clair counties in southeastern Michigan in the communities where the Bank's respective offices are located.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.